PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 [Yahoo! Finance]
PainReform Ltd. - Ordinary Shares (PRFX)
Company Research
Source: Yahoo! Finance
TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. PainReform previously disclosed initial topline data from its Phase 3 clinical trial in which it reported that it demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery. Yet, at that time, data pertaining to the last 24-hour period of the 72-hour study follow-up was unclear, and efforts were made to resolve the incoherence and complete the analysis. Following further investigation, PainReform has determined that the data from the final 24-hour period could not be clarified to satisfy the study's primary endpoint 72 hours requirement, and
Show less
Read more
Impact Snapshot
Event Time:
PRFX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRFX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRFX alerts
High impacting PainReform Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRFX
News
- PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110GlobeNewswire
- PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialGlobeNewswire
- PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement [Yahoo! Finance]Yahoo! Finance
- PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementGlobeNewswire
PRFX
Sec Filings
- 1/2/25 - Form 424B5
- 1/2/25 - Form 6-K
- 12/27/24 - Form 6-K
- PRFX's page on the SEC website